A detailed history of Zacks Investment Management transactions in Veracyte, Inc. stock. As of the latest transaction made, Zacks Investment Management holds 32,995 shares of VCYT stock, worth $1.35 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
32,995
Holding current value
$1.35 Million
% of portfolio
0.01%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$21.0 - $35.25 $692,895 - $1.16 Million
32,995 New
32,995 $1.12 Million

Others Institutions Holding VCYT

About VERACYTE, INC.


  • Ticker VCYT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,575,904
  • Market Cap $2.93B
  • Description
  • Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...
More about VCYT
Track This Portfolio

Track Zacks Investment Management Portfolio

Follow Zacks Investment Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Zacks Investment Management, based on Form 13F filings with the SEC.

News

Stay updated on Zacks Investment Management with notifications on news.